Lynch syndrome-associated colorectal cancers are known to evoke a strong reaction from the host's immune system. We discovered that early-staged tumors were more densely infiltrated by activated CD8+ T-cells than tumors diagnosed at advanced stages. Moreover, we observed an immune cell population that was specifically associated with non-metastasized Lynch syndrome colorectal cancers. Those cells lacked most common lymphocytic surface antigens.
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Introduction:
Expression of Human Leukocyte Antigen (HLA) class I/antigen complexes, in human cells, is essential for a competent immune surveillance (1) . CD8+ T-cells are capable of recognizing and eliminating target cells that present non-self antigens in an HLA class I context (2) . Accordingly, HLA class I loss is interpreted as a mechanism, adopted by tumors, to escape immune surveillance and thereby avoid tumor cell recognition and destruction (3) . We, and others, previously reported that the majority of DNA mismatch and base excision repair deficient colorectal cancers lose HLA class I expression (4-7).
Those include sporadic mismatch repair deficient as well as Lynch syndrome colorectal cancers and MUTYH-associated polyposis colorectal cancers, respectively. The frequency of HLA class I deficiencies in these tumors was found to be considerably higher than the one observed for DNA repair proficient colorectal cancers (5, 7) . Both mismatch and base excision repair deficient colorectal cancers are thought to be particularly prone to evoke anti-tumor immune responses due to their pronounced mutator phenotypes (8) . Such immune reaction will act as a vector of selective pressure that favors the outgrowth of tumor clones that acquired immune evasive phenotypes.
Multiple mechanisms have been shown to underlie defects in HLA class I expression by tumor cells; they include mutations in the individual HLA class I genes, HLA-A, -B and -C, located on chromosome 6p21.3 (9) ; loss of heterozygosity at 6p21.3 (10) ; mutations in β2-microglobulin (β2M) (11) , the molecular chaperone required for the cell surface expression of HLA class I antigens; and defects in components of the HLA class I-associated antigen-processing machinery (12, 13) . For unknown reasons ɴ2M defects were preferentially associated with HLA class I loss in hereditary colorectal cancers (Lynch syndrome and MAP), while sporadic mismatch repair deficient tumors were frequently affected by antigen-processing machinery defects (5, 14) .
The loss of HLA class I expression, in mismatch and base excision repair deficient colorectal cancers, constitutes a strong handicap for the employment of T-cell based immunotherapeutical approaches (15, 16) . On the other hand, evidence for T-cell mediated anti-tumor immune responses could support the development of prophylactic vaccination strategies based on peptides that are (17, 18) . This approach is of particular importance for individuals carrying an increased risk for developing colorectal cancer at an early age. Lynch syndrome is an autosomal, dominant disease caused by the germline inactivation of one copy of either MLH1, MSH2, MSH6 or PMS2 mismatch repair genes (19) . Lynch syndrome patients have an increased lifetime risk of developing colorectal cancer, as well as other cancer types, when compared to the general population (20) . Currently, endoscopic surveillance constitutes the most effective approach to increase life expectancy of affected individuals (21) .
The development of T-cell based prophylactic vaccination strategies, for Lynch syndrome patients, requires additional evidence that T-cells are the drivers of immune selection in Lynch colorectal carcinomas. It has been previously reported that colorectal cancers carrying HLA class I defects are more densely infiltrated by T-cells (22) (23) (24) . However, these observations were not reproduced specifically in cohorts of mismatch repair deficient tumors. Accordingly, those reports might carry a possible bias: since both pronounced lymphocytic infiltration and HLA class I loss are hallmarks of mismatch repair deficient tumors it is difficult to establish a causal relation between the presence of lymphocytes and HLA class I abnormalities on consecutive series of colorectal cancers (8, 25, 26) . Therefore, the current study was performed on a homogeneous cohort of genetically proven Lynch colorectal carcinomas. We sought to characterize and quantify the lymphocytic infiltration present in Lynch colorectal carcinomas and relate it with their HLA class I expression status and clinicopathological stage. 
Immunohistochemistry:
Expression of HLA class I and β2M were assessed by means of a two-step indirect immunohistochemistry procedure on 4 μm tissue sections. Following deparaffinization and rehydration, the tissue sections underwent heat-mediated antigen retrieval in a 10 mM citrate buffer solution (pH 6). After cooling, endogenous peroxidase activity blockage was performed with a 0.3% hydrogen peroxide/methanol solution. Thereafter, the sections were incubated over-night with one of the following primary antibodies: the monoclonal antibody (MAb) HCA2, which recognizes ɴ2M-free HLA-A (except -A24), -B7301, and -G heavy chains (28, 29) ; the MAb HC10, which recognizes a determinant expressed on all ɴ2M-free HLA-B and -C heavy chains and on ɴ2M-free HLA-A10, -A28, -A29, -A30, -A31, -A32, and -A33 heavy chains (29, 30) A double-staining immunohistochemistry procedure was carried-out to study the morphology of CD3-/CD8-/GZMB+ cells. Tissue sections were treated as described for the HLA class I and β2M staining but heat-mediated antigen retrieval was done in a 1 mM EDTA solution (pH 9) instead. Tissue sections were incubated over-night with a mixture of anti-CD8 (4B11, IgG2b) and anti-granzyme B (GZMB) (GrB-7, IgG2a) antibodies. Further detail on the primary antibodies is provided in Supplementary Table 1 were performed with the ZEN2009 LE software (Carl Zeiss). Negative controls were generated by replacing primary antibodies by a 1% BSA/PBS solution.
Statistical analyses:
All statistical tests and graph construction were performed with Graphpad PRISM (version 5.04). The
Mann-Whitney U test was employed when assessing the differences in the amount of lymphocytic infiltrate between HLA class I phenotypes and lymph node negative and positive tumors. Analysis of variance (ANOVA) was performed for comparing lymphocyte density amongst the different T tumor stages (TNM classification).
Research. Figure 1) . The latter presented fields where tumor cells conserved membranous expression of HLA class I together with additional tumor areas where HLA class I expression was completely lost (Supplementary Figure 1 C, D) . HLA class I alterations were accompanied by aberrant ɴ2M expression in 51% of cases (Table 1) A population of cells with a CD3-/CD8-/GZMB+ phenotype was detected in 82% of cases at various frequencies (Figure 1 C, D) . These cells were often localized in the stromal compartment, immediately adjacent to the tumor fields, but less frequently within the epithelium. CD3-/CD8-/GZMB+ cells were mostly restricted to HLA class I negative tumors (P = .004) (Figure 2 D) . Remarkably, abundance of the elusive CD3-/CD8-/GZMB+ cell population not only correlated with HLA negative tumors, but was also characteristic for lymph node negative carcinomas (P < .01) (Figure 3 E, F) . All Lynch carcinomas with more than 10 CD3-/CD8-/GZMB+ cells per mm 2 of tumor area did not present lymph node metastases. Furthermore, the only two cases presenting metastases at distant organs also carried lower numbers of CD3-/CD8-/GZMB+ cells (0 and 7 cells/mm 2 ). None of the CD3+ lymphocyte populations related to the tumor's lymph node status.
Characterization of the CD3-/CD8-/GZMB+ cell population
The potential clinical significance of the CD3-/CD8-/GZMB+ cell population in the progression of Author Manuscript Published OnlineFirst on January 18, 2012; DOI: 10.1158/1078-0432.CCR- expression was assessed simultaneously with CD8 and GZMB markers (antibody description in Supplementary Table 1 ).
The only marker that clearly associated with the CD3-/CD8-/GZMB+ cell population was CD45 ( Figure   1 E) , thus confirming the hematopoietic nucleated lineage of these cells. CD56+ cells were rare and located nearby blood vessels (Supplementary Figure 2 A ). CD16 cells were abundant but did not colocalize with GZMB positivity (Supplementary Figure 2 B ). CD57+/CD8-cells were often found in the tumor stroma and some displayed positivity for GZMB but CD57 failed to co-localize with the majority of CD8-/GZMB+ cells (Supplementary Figure 2 C ). All other investigated markers did not colocalize with these cells, despite the presence of internal positive controls for the majority (data not shown). No NKp46+ cells were found in the tumor tissues. We detected NKp46 expression in tonsil tissues in order to rule out a failure of the staining procedure.
As GZMB expression could be derived from granulocytes, we performed a bright-field, double staining of CD8 and GZMB together with hematoxylin counter-staining in order to discern the nuclear morphology of CD8-/GZMB+ cells. The nuclei from CD8-/GZMB+ cells were non-lobated and easily 13 absent in HLA class I positive tumors. Strikingly, the presence of CD3-/CD8-/GZMB+ cells, in primary tumors, was highly predictive for the absence of lymph node metastases. Altogether, these observations compelled us to further characterize this population with focus on NK cell markers.
NK cells are CD3 negative cells possessing cytolytic activity, which can be triggered by the absence of HLA class I expression in target cells (37) . They, thus, constitute an important component of the innate immune system, responsible for dealing with cells lacking important host markers -missing self hypothesis (38) . Accordingly, NK cells have been regarded as promising vectors for the treatment of HLA class I negative cancers (39) . It is thought that tumor cells compensate HLA class I loss by favoring the expression of additional NK-inactivating ligands and by losing antagonist ligands with NK-activating properties (40) . Expression of HLA-G, an NK cell inhibitory ligand, was previously associated with a worse prognosis in colorectal cancer (41) . We investigated its expression in a fraction of tumors composing the current cohort. HLA-G expression was never membranous and only detected in 16% of tumors (data not shown).
Several molecules have been proposed to be characteristic for NK cells or, at least, expressed by certain NK cell subsets (40) . Our investigation included CD56, NKp46 and CD16, among others. All these markers were absent in the CD3-/CD8-/GZMB+ cell population, thus not supporting their classification as NK cells. Several other markers were investigated which in turn excluded that these cells were mast cells or other granulocytes, macrophages or ɶɷ T-cells. The only marker that clearly associated with the CD3-/CD8-/GZMB+ cell population was CD45, which confirmed their hematopoietic nucleated lineage.
Considering that tumor staging is still the most important prognostic factor, in colorectal cancer, the findings presented in this work might be of great relevance. We found a clear association between the type and density of immune cells, present in the primary tumor, and its clinicopathological stage. proposed that the type, density, and location of immune cells were better predictors of patient outcome than staging (45) . However, the majority of studies did not discriminate between mismatch repair deficient and proficient colorectal cancers. Hence, the current study is the first to focus specifically on Lynch colorectal carcinomas.
While immune cells are important drivers of tumor selection, they could also hold the key for novel therapeutic or preventive interventions. The prophylactic vaccination of Lynch syndrome patients, with recurrent tumor antigens, could elicit an early and robust CD8+ T-cell immune response (17, 18) . 
